BCAB Stock Overview
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
BioAtla, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.44 |
52 Week High | US$4.07 |
52 Week Low | US$1.24 |
Beta | 1 |
1 Month Change | 21.13% |
3 Month Change | 39.84% |
1 Year Change | 39.84% |
3 Year Change | -93.27% |
5 Year Change | n/a |
Change since IPO | -88.91% |
Recent News & Updates
Recent updates
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 14Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?
Nov 05We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Jun 27Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 24BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Sep 27BioAtla: Back From The Dead
Sep 23BioAtla: Promising Signal In NSCLC, But Concerns Remain
Aug 23BioAtla reports Q2 results
Aug 09We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate
May 11Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth
Jan 06BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Jul 24Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?
Mar 16Shareholder Returns
BCAB | US Biotechs | US Market | |
---|---|---|---|
7D | 42.7% | 0.9% | 0.4% |
1Y | 39.8% | 10.3% | 28.8% |
Return vs Industry: BCAB exceeded the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: BCAB exceeded the US Market which returned 28.8% over the past year.
Price Volatility
BCAB volatility | |
---|---|
BCAB Average Weekly Movement | 16.8% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCAB's share price has been volatile over the past 3 months.
Volatility Over Time: BCAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 65 | Jay Short | https://www.bioatla.com |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer that is in Phase II clinical trial. Its products under clinical development include BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer which is in Phase II clinical trial; BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer that is in Phase II clinical trial; and BA3182, a CAB bispecific candidate that is in Phase I clinical trial for the treatment of adenocarcinomas.
BioAtla, Inc. Fundamentals Summary
BCAB fundamental statistics | |
---|---|
Market cap | US$166.41m |
Earnings (TTM) | -US$123.46m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs BCAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BCAB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$103.73m |
Gross Profit | -US$103.73m |
Other Expenses | US$19.73m |
Earnings | -US$123.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.57 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did BCAB perform over the long term?
See historical performance and comparison